Relative Biological Effectiveness of HZE Particles for Chromosomal Exchanges and Other Surrogate Cancer Risk Endpoints

PLoS One. 2016 Apr 25;11(4):e0153998. doi: 10.1371/journal.pone.0153998. eCollection 2016.

Abstract

The biological effects of high charge and energy (HZE) particle exposures are of interest in space radiation protection of astronauts and cosmonauts, and estimating secondary cancer risks for patients undergoing Hadron therapy for primary cancers. The large number of particles types and energies that makeup primary or secondary radiation in HZE particle exposures precludes tumor induction studies in animal models for all but a few particle types and energies, thus leading to the use of surrogate endpoints to investigate the details of the radiation quality dependence of relative biological effectiveness (RBE) factors. In this report we make detailed RBE predictions of the charge number and energy dependence of RBE's using a parametric track structure model to represent experimental results for the low dose response for chromosomal exchanges in normal human lymphocyte and fibroblast cells with comparison to published data for neoplastic transformation and gene mutation. RBE's are evaluated against acute doses of γ-rays for doses near 1 Gy. Models that assume linear or non-targeted effects at low dose are considered. Modest values of RBE (<10) are found for simple exchanges using a linear dose response model, however in the non-targeted effects model for fibroblast cells large RBE values (>10) are predicted at low doses <0.1 Gy. The radiation quality dependence of RBE's against the effects of acute doses γ-rays found for neoplastic transformation and gene mutation studies are similar to those found for simple exchanges if a linear response is assumed at low HZE particle doses. Comparisons of the resulting model parameters to those used in the NASA radiation quality factor function are discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosomes*
  • Cosmic Radiation*
  • Dose-Response Relationship, Radiation
  • Humans
  • Neoplasms / genetics
  • Neoplasms / physiopathology*
  • Relative Biological Effectiveness

Grants and funding

This work was supported by the DOE Low Dose Program (grant number DE-AI02-10ER64969) to FAC, and the University of Nevada, Las Vegas. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.